Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
Family physicians and other primary care providers don’t mind being held to account for care quality by healthcare administrators. The rub is that multiple other stakeholders often demand similar levels of answerability, pulling the doctors in different directions at once.
Pharmaceutical companies are spending close to $10 billion per year on direct-to-consumer advertising in the U.S. Only the entertainment industry spends more. Is that a good thing?
The idea was floated as part of a proposed budget for the state released by Democrats in the Senate. If passed, only the top 2% of corporations in California would be impacted. The levy would generate $5 billion to $8 billion annually for Medicaid.
The maker of popular GLP-1 agonists Wegovy and Ozempic said technology from OpenAI, the company behind ChatGPT, will allow it to sift through and make sense of massive datasets to identify potential new uses for its diabetes and obesity treatments.
Liberator Medical Supply was accused of offering doctors kickbacks, such as discounted and free supplies, in exchange for filling prescriptions with its products.
The last count submitted to HHS in October pegged the number at 100 million. Now that figure sits at 190 million, and the company continues its investigation.
The Centers for Medicare & Medicaid Services appealed a court ruling that ordered the agency to change the star rating for UnitedHealthcare's Medicare Part D plans, which had been reduced due to a disputed phone call. CMS has now dropped the appeal.
When Larry Ellison talks about healthcare AI, people invest. At least, that’s what happened after the Oracle chairman enthused over AI’s potential to cook up vaccines for cancer.
Tim Noel is taking the reins of the insurance giant in the aftermath of the murder of its previous CEO, Brian Thompson. Noel has been with the company since 2007.
The agency found 82 cases of anaphylaxis associated with glatiramer acetate, sold under the brand names Copaxone and Glatopa, including 19 that emerged after patients had been taking these drugs for more than a year.